Published in Expert Opin Ther Targets on May 01, 2007
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis (2010) 3.90
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood (2009) 2.43
IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci (2012) 2.15
Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci (2012) 2.01
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest (2014) 2.01
Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis (2009) 1.72
The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics (2014) 1.57
Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther (2011) 1.51
Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem (2011) 1.29
Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol (2012) 1.22
Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis (2011) 1.20
Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis (2011) 1.18
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. Eur J Immunol (2009) 1.07
Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol (2013) 1.07
Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J Immunol (2010) 1.07
Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biol (2010) 1.02
Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology (2010) 1.01
Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell (2008) 1.01
Dietary blue pigments derived from genipin, attenuate inflammation by inhibiting LPS-induced iNOS and COX-2 expression via the NF-κB inactivation. PLoS One (2012) 1.01
Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res (2009) 1.01
Daily genetic profiling indicates JAK/STAT signaling promotes early hepatic stellate cell transdifferentiation. World J Gastroenterol (2010) 1.01
The role of cytokines in Guillain-Barré syndrome. J Neurol (2010) 1.00
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag (2008) 1.00
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol (2012) 1.00
Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol (2009) 0.98
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer (2013) 0.96
A machine learning approach for genome-wide prediction of morbid and druggable human genes based on systems-level data. BMC Genomics (2010) 0.95
Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine (2007) 0.94
IL-6-STAT3 signaling and premature senescence. JAKSTAT (2013) 0.93
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer (2013) 0.93
Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism. J Transl Med (2013) 0.91
Metallothionein and brain inflammation. J Biol Inorg Chem (2011) 0.90
Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol (2011) 0.90
A quantitative high-throughput screen for modulators of IL-6 signaling: a model for interrogating biological networks using chemical libraries. Mol Biosyst (2009) 0.90
Role of miRNA let-7 and its major targets in prostate cancer. Biomed Res Int (2014) 0.89
An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet (2009) 0.89
Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol (2014) 0.89
Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev (2015) 0.89
Autocrine effects of interleukin-6 mediate acute-phase proinflammatory and tissue-reparative transcriptional responses of canine bladder mucosa. Infect Immun (2010) 0.88
Novel targeted therapies for autoimmunity. Curr Opin Immunol (2009) 0.87
5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties. Bioorg Med Chem Lett (2012) 0.86
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med (2011) 0.86
IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes. J Immunol (2011) 0.85
Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin. Tissue Eng Part A (2014) 0.85
Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis Mice. Int J Inflam (2014) 0.84
Transcriptional activation of endothelial cells by TGFβ coincides with acute microvascular plasticity following focal spinal cord ischaemia/reperfusion injury. ASN Neuro (2009) 0.84
Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol (2013) 0.84
Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor. Anticancer Agents Med Chem (2012) 0.84
Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop. Oncotarget (2015) 0.82
Interleukin-6 (IL-6) receptor/IL-6 fusion protein (Hyper IL-6) effects on the neonatal mouse brain: possible role for IL-6 trans-signaling in brain development and functional neurobehavioral outcomes. Brain Behav Immun (2012) 0.82
Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model. Clin Rheumatol (2014) 0.81
Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy. Oxf Med Case Reports (2016) 0.81
A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol (2014) 0.81
A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT Pharmacometrics Syst Pharmacol (2014) 0.81
Angiogenic and innate immune responses triggered by PRP in tendon cells are not modified by hyperuricemia. Muscles Ligaments Tendons J (2014) 0.81
Blockade of recombinant human IL-6 by tocilizumab suppresses matrix metalloproteinase-9 production in the C28/I2 immortalized human chondrocyte cell line. Integr Mol Med (2015) 0.80
Special regulatory T-cell review: Suppressors regulated but unsuppressed. Immunology (2008) 0.79
Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatol (2009) 0.79
Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis. Clin Rheumatol (2015) 0.78
Attractive shedding. Blood (2007) 0.78
Expression of pancreatitis-associated protein after traumatic brain injury: a mechanism potentially contributing to neuroprotection in human brain. Cell Mol Neurobiol (2011) 0.78
Genetics of asthma susceptibility and severity. Clin Chest Med (2012) 0.78
Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer (2016) 0.77
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol (2017) 0.77
TL1A induces TCR independent IL-6 and TNF-α production and growth of PLZF⁺ leukocytes. PLoS One (2014) 0.77
IL-6 Signaling in Myelomonocytic Cells Is Not Crucial for the Development of IMQ-Induced Psoriasis. PLoS One (2016) 0.77
Kitasato symposium 2009: new prospects for cytokine inhibition. Arthritis Res Ther (2009) 0.77
Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation (2016) 0.76
Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling. Sci Rep (2017) 0.75
IL-6 and IL-17A degradation by mast cells is mediated by a serglycin:serine protease axis. Immun Inflamm Dis (2015) 0.75
Prolactin and Dehydroepiandrosterone Levels in Women with Systemic Lupus Erythematosus: The Role of the Extrapituitary Prolactin Promoter Polymorphism at -1149G/T. J Immunol Res (2015) 0.75
Dexamethasone and salbutamol stimulate human lung fibroblast proliferation. World Allergy Organ J (2011) 0.75
Monocyte Subsets Coregulate Inflammatory Responses by Integrated Signaling through TNF and IL-6 at the Endothelial Cell Interface. J Immunol (2017) 0.75
Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol (2012) 0.75
Acute exposure to 50-Hz magnetic fields increases interleukin-6 in young healthy men. J Clin Immunol (2011) 0.75
Phosphorylation of STAT proteins by recombinant human IL-6 in immortalized human chondrocyte cell lines, T/C28a2 and C28/I2. J Inflamm Res (2017) 0.75
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol (2006) 3.45
Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet (2004) 3.19
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology (2003) 2.58
Yeast Mph1 helicase dissociates Rad51-made D-loops: implications for crossover control in mitotic recombination. Genes Dev (2009) 2.43
Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem (2003) 2.26
IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res (2005) 2.17
p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol (2002) 2.14
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem (2005) 2.01
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci (2005) 2.00
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med (2005) 1.88
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med (2011) 1.87
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol (2010) 1.70
G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol (2009) 1.65
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood (2010) 1.56
Uncovering the evolutionary history of innate immunity: the simple metazoan Hydra uses epithelial cells for host defence. Dev Comp Immunol (2008) 1.55
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol (2008) 1.42
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
A short isoform of NOD2/CARD15, NOD2-S, is an endogenous inhibitor of NOD2/receptor-interacting protein kinase 2-induced signaling pathways. Proc Natl Acad Sci U S A (2006) 1.37
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol (2010) 1.35
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene (2005) 1.30
Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem (2011) 1.29
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2011) 1.29
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet (2013) 1.23
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci (2005) 1.23
Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 1.23
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol (2009) 1.14
Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des (2009) 1.12
Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci (2014) 1.10
Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol (2009) 1.08
The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem (2002) 1.08
ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta (2009) 1.07
The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem (2004) 1.07
Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol J (2008) 1.05
Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem (2003) 1.04
A role for membrane-bound CD147 in NOD2-mediated recognition of bacterial cytoinvasion. J Cell Sci (2008) 1.03
Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 1.03
TLR ligand-induced podosome disassembly in dendritic cells is ADAM17 dependent. J Cell Biol (2008) 1.02
Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab (2006) 1.02
T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol (2004) 1.01
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2012) 1.01
Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrob Agents Chemother (2010) 1.01
Functional characterization of two novel point mutations in the CYP21 gene causing simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab (2004) 1.00
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell (2006) 1.00
Hydramacin-1, structure and antibacterial activity of a protein from the basal metazoan Hydra. J Biol Chem (2008) 1.00
Caenopores are antimicrobial peptides in the nematode Caenorhabditis elegans instrumental in nutrition and immunity. Dev Comp Immunol (2009) 1.00
The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem (2005) 0.99
ELPylated anti-human TNF therapeutic single-domain antibodies for prevention of lethal septic shock. Plant Biotechnol J (2011) 0.98
Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody. Plant Biotechnol J (2009) 0.98
Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun (2009) 0.98
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
gp130 dimerization in the absence of ligand: preformed cytokine receptor complexes. Biochem Biophys Res Commun (2006) 0.97
Role of IL-6 trans-signaling in CCl₄induced liver damage. Biochim Biophys Acta (2010) 0.97
Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-beta1. FASEB J (2004) 0.97
IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol (2012) 0.96
Reaction mechanism and structural model of ADP-forming Acetyl-CoA synthetase from the hyperthermophilic archaeon Pyrococcus furiosus: evidence for a second active site histidine residue. J Biol Chem (2008) 0.95
Solution structure of the pore-forming protein of Entamoeba histolytica. J Biol Chem (2004) 0.94
The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes. Dev Comp Immunol (2009) 0.93
Congenital lipoid adrenal hyperplasia: functional characterization of three novel mutations in the STAR gene. J Clin Endocrinol Metab (2010) 0.93
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int (2014) 0.93
"Activated" STAT proteins: a paradoxical consequence of inhibited JAK-STAT signaling in cytomegalovirus-infected cells. J Immunol (2013) 0.92
Structure and mode of action of the antimicrobial peptide arenicin. Biochem J (2008) 0.92
Interleukin-6 and interleukin-11: same same but different. Biol Chem (2013) 0.92
Unusual function of the activation loop in the protein kinase DYRK1A. Biochem Biophys Res Commun (2003) 0.91
Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem (2012) 0.91
Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. Eur J Cell Biol (2010) 0.91
Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem (2008) 0.91